Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
Clinical trial NCT07153497 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07153497
- Sponsor
- National Cancer Institute (NCI)
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-27
- Primary completion
- 2030-04-26
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.